tiprankstipranks
Trending News
More News >
Ampio Pharmaceuticals (AMPE)
OTHER OTC:AMPE
US Market
Advertisement

Ampio Pharmaceuticals (AMPE) Price & Analysis

Compare
508 Followers

AMPE Stock Chart & Stats


Ampio Pharmaceuticals News

AMPE FAQ

What was Ampio Pharmaceuticals’s price range in the past 12 months?
Ampio Pharmaceuticals lowest stock price was <$0.01 and its highest was $0.13 in the past 12 months.
    What is Ampio Pharmaceuticals’s market cap?
    Ampio Pharmaceuticals’s market cap is $3.29K.
      When is Ampio Pharmaceuticals’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Ampio Pharmaceuticals’s earnings last quarter?
      Ampio Pharmaceuticals released its earnings results on May 11, 2023. The company reported -$0.264 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.264.
        Is Ampio Pharmaceuticals overvalued?
        According to Wall Street analysts Ampio Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Ampio Pharmaceuticals pay dividends?
          Ampio Pharmaceuticals does not currently pay dividends.
          What is Ampio Pharmaceuticals’s EPS estimate?
          Ampio Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Ampio Pharmaceuticals have?
          Ampio Pharmaceuticals has 1,135,358 shares outstanding.
            What happened to Ampio Pharmaceuticals’s price movement after its last earnings report?
            Ampio Pharmaceuticals reported an EPS of -$0.264 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Ampio Pharmaceuticals?
              Currently, no hedge funds are holding shares in AMPE

              Company Description

              Ampio Pharmaceuticals

              Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.

              Ampio Pharmaceuticals (AMPE) Earnings & Revenues

              Similar Stocks
              Company
              Price & Change
              Follow
              Salarius Pharmaceuticals
              Quoin Pharmaceuticals
              Processa Pharmaceuticals
              GRI Bio
              Onconetix

              Ownership Overview

              0.04%99.96%
              Insiders
              Mutual Funds
              0.04% Other Institutional Investors
              99.96% Public Companies and
              Individual Investors

              Options Prices

              Currently, No data available
              ---
              Popular Stocks
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis